FDA Nod Allows Edwards to Treat Pulmonary Regurgitation Patients

FDA Nod Allows Edwards to Treat Pulmonary Regurgitation Patients

Source: 
Medical Devices and Diagnostics Industry
snippet: 

Edwards Lifesciences is closing out 2021 by nabbing a new approval from FDA. The Irvine, CA-based company said it won the nod for the use of the Edwards Sapien 3 transcatheter valve with the Alterra adaptive prestent for patients with severe pulmonary regurgitation.